Summary
CBDVA is the carboxylic-acid precursor of cannabidivarin (CBDV); heating or vaping will largely decarboxylate it into CBDV. Pre-clinical data suggest anticonvulsant, anti-inflammatory, and 5-HT1A-mediated anti-nausea properties similar to CBDA, but human data are sparse. Like CBD, CBDVA appears to inhibit CYP3A4, CYP2C19 and CYP2C9, so therapeutic drug monitoring is advised when combined with narrow-therapeutic-index medications (e.g., warfarin, clobazam, tacrolimus). Because it is non-intoxicating, subjective effects are subtle; many users report clearer focus and reduced anxiety rather than overt euphoria. Long-term safety data are lacking; start low, especially if you have liver disease or take hepatically-metabolized drugs.
Dose Information
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset | After Effects |
|---|---|---|---|---|---|
| Oral | 30-90 min | 30-60 min | 2-4 hrs | 2-4 hrs | 12 hrs |
| Sublingual | 15-45 min | 20-40 min | 1.5-3 hrs | 1.5-3 hrs | 8 hrs |
| Vaporized | 1-5 min | 5-15 min | 10-30 min | 1-2 hrs | 6 hrs |
Tolerance
Build-up
develops over weeks of regular use via CB1 receptor downregulation
Reset
2–4 weeks for most users; heavy users may need longer
Effects
Positive
- Anxiolysis
- Reduced inflammation perception
- Anticonvulsant effects
- Mild stimulation at low doses
- Antiemetic effects
Negative
- Sedation at higher doses
Positive
- Subtle relaxation
- Mild mood elevation
Negative
- Increased focus